- Home
- HALO vs EXAS Comparison
HALO vs EXAS Comparison
Compare HALO & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- EXAS
- Stock Information
- Founded
- HALO 1998
- EXAS 1995
- Country
- HALO United States
- EXAS United States
- Employees
- HALO N/A
- EXAS N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- EXAS Medical Specialities
- Sector
- HALO Health Care
- EXAS Health Care
- Exchange
- HALO Nasdaq
- EXAS Nasdaq
- Market Cap
- HALO 7.4B
- EXAS 8.8B
- IPO Year
- HALO N/A
- EXAS N/A
- Fundamental
- Price
- HALO $61.06
- EXAS $43.04
- Analyst Decision
- HALO Buy
- EXAS Strong Buy
- Analyst Count
- HALO 9
- EXAS 18
- Target Price
- HALO $61.63
- EXAS $70.59
- AVG Volume (30 Days)
- HALO 1.4M
- EXAS 2.6M
- Earning Date
- HALO 05-06-2025
- EXAS 05-07-2025
- Dividend Yield
- HALO N/A
- EXAS N/A
- EPS Growth
- HALO 63.33
- EXAS N/A
- EPS
- HALO 3.43
- EXAS N/A
- Revenue
- HALO $1,015,324,000.00
- EXAS $2,758,867,000.00
- Revenue This Year
- HALO $20.06
- EXAS $13.02
- Revenue Next Year
- HALO $23.87
- EXAS $13.02
- P/E Ratio
- HALO $17.78
- EXAS N/A
- Revenue Growth
- HALO 22.44
- EXAS 10.37
- 52 Week Low
- HALO $37.73
- EXAS $40.62
- 52 Week High
- HALO $65.53
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- HALO 68.07
- EXAS 29.29
- Support Level
- HALO $60.38
- EXAS $44.45
- Resistance Level
- HALO $63.11
- EXAS $46.99
- Average True Range (ATR)
- HALO 1.73
- EXAS 2.45
- MACD
- HALO 0.12
- EXAS -0.22
- Stochastic Oscillator
- HALO 66.99
- EXAS 9.95
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.